Loading...
•
Jun 30, 2022
Applied Therapeutics Q2 2022 Earnings Report
Reported financial results for the second quarter ended June 30, 2022.
Key Takeaways
Applied Therapeutics reported financial results for the second quarter ended June 30, 2022, and continued progress across its three registrational Phase 3 trials in Galactosemia, SORD Deficiency and Diabetic Cardiomyopathy.
Completed public equity offering with gross proceeds of $30 million.
Granted orphan medicinal product designation by the EMA for AT-007 for treatment of Galactosemia.
Continued progress in three registrational Phase 3 trials in areas of high unmet medical need.
Multiple clinical milestones expected in 2H 2022, including Galactosemia 12 month data analysis, SORD Deficiency biomarker data, and DbCM full enrollment.
Applied Therapeutics
Applied Therapeutics
Forward Guidance
The company expects to complete its 12 month analysis in the pediatric Galactosemia study in September, and plan to announce full enrollment in both SORD Deficiency and DbCM soon. They expect these catalysts to bring them closer to their goal of delivering meaningful new treatments to patients in need.